HLA-DQ2 homozygosis increases tTGA levels at diagnosis but does not influence the clinical phenotype of coeliac disease A multicentre study /
Magnitude of gluten-specific T-cell responses in coeliac disease (CD) might be dependent on HLA-DQ2 gene dose. We aimed to investigate the effects of HLA-DQB1*02 allele dose on clinical outcomes.We reviewed the charts of all coeliac patients attending to three Hungarian university clinics after 1997...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | INTERNATIONAL JOURNAL OF IMMUNOGENETICS
46 No. 2 |
| doi: | 10.1111/iji.12415 |
| mtmt: | 30449576 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/22004 |
| LEADER | 02751nab a2200313 i 4500 | ||
|---|---|---|---|
| 001 | publ22004 | ||
| 005 | 20210803103842.0 | ||
| 008 | 210803s2019 hu o 0|| zxx d | ||
| 022 | |a 1744-3121 | ||
| 024 | 7 | |a 10.1111/iji.12415 |2 doi | |
| 024 | 7 | |a 30449576 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Bajor Judit | |
| 245 | 1 | 0 | |a HLA-DQ2 homozygosis increases tTGA levels at diagnosis but does not influence the clinical phenotype of coeliac disease |h [elektronikus dokumentum] : |b A multicentre study / |c Bajor Judit |
| 260 | |c 2019 | ||
| 300 | |a 74-81 | ||
| 490 | 0 | |a INTERNATIONAL JOURNAL OF IMMUNOGENETICS |v 46 No. 2 | |
| 520 | 3 | |a Magnitude of gluten-specific T-cell responses in coeliac disease (CD) might be dependent on HLA-DQ2 gene dose. We aimed to investigate the effects of HLA-DQB1*02 allele dose on clinical outcomes.We reviewed the charts of all coeliac patients attending to three Hungarian university clinics after 1997 and included those patients, who (a) were diagnosed with CD, (b) underwent high-resolution HLA typing and (c) were ≥18 years at the time of data collection. HLA typing was performed to determine DQB1*02 allele dose. Patients were divided into risk groups by DQB1*02 allele dose, as follows: high-, intermediate- and low-risk groups corresponded to a double, single and zero doses, respectively. We used ANOVA and Pearson's chi-squared test to explore association between HLA risk and clinical variables.A total of 727 coeliac patients attended the clinics but only 105 (14.4%) patients were eligible for inclusion. High, intermediate and low HLA risk patients comprised 35.3%, 52.3% and 12.3% of the study population, respectively. Double dose of HLA-DQB1*02 was more frequent in patient with high tTGA level (>10 times the upper limit of normal; p = 0.045). Gene dose was not associated with younger age at diagnosis (p = 0.549), gender (p = 0.739), more severe diagnostic histology (p = 0.318), more frequent classical presentation (p = 0.846), anaemia (p = 0.611), metabolic bone disease (p = 0.374), dermatitis herpetiformis (p = 0.381) and autoimmune diseases (p = 0.837).Our study shows a significant gene dose effect in terms of tTGA level at diagnosis, but no significant association between HLA-DQB1*02 allele dose and the clinical outcomes in CD. | |
| 700 | 0 | 1 | |a Szakács Zsolt |e aut |
| 700 | 0 | 1 | |a Juhász Márk |e aut |
| 700 | 0 | 1 | |a Papp Mária |e aut |
| 700 | 0 | 1 | |a Kocsis Dorottya |e aut |
| 700 | 0 | 1 | |a Szegedi Éva |e aut |
| 700 | 0 | 1 | |a Földi Ildikó |e aut |
| 700 | 0 | 2 | |a Borbásné Farkas Kornélia |e aut |
| 700 | 0 | 2 | |a Hegyi Péter |e aut |
| 700 | 0 | 2 | |a Vincze Áron |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/22004/1/BajorIntJImmunogenet2019.pdf |z Dokumentum-elérés |